Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Gains from Sales and Divestitures for 16 consecutive years, with $194488.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 8.77% to $194488.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $194488.0 through Dec 2025, up 8.77% year-over-year, with the annual reading at $194488.0 for FY2025, 8.77% up from the prior year.
  • Gains from Sales and Divestitures hit $194488.0 in Q4 2025 for Ironwood Pharmaceuticals, up from $178800.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.7 million in Q4 2021 to a low of $71588.0 in Q4 2023.
  • Historically, Gains from Sales and Divestitures has averaged $477866.2 across 5 years, with a median of $194488.0 in 2025.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 85.47% in 2022 and later surged 149.76% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $1.7 million in 2021, then tumbled by 85.47% to $246710.0 in 2022, then crashed by 70.98% to $71588.0 in 2023, then soared by 149.76% to $178800.0 in 2024, then rose by 8.77% to $194488.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for IRWD at $194488.0 in Q4 2025, $178800.0 in Q4 2024, and $71588.0 in Q4 2023.